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Epstein–Barr virus (EBV) replicates as a stable multicopy episome in latently infected mammalian cells. Latent cycle DNA
replication requires only two viral elements, the cis-acting origin of plasmid replication (oriP) and the trans-acting origin
binding protein (EBNA1). EBNA1 binds multiple recognition sites in oriP, but has no other enzymatic activities associated with
replication functions. To identify human cellular proteins that mediate EBNA1 function, we designed a one-hybrid assay in
yeast to select for proteins that bind to EBNA1 when bound to oriP in vivo. A human cDNA encoding the Rch1/hSRP1a/
importina protein was isolated and shown to bind to full-length EBNA1, but not to an amino terminal deletion mutant of EBNA1
when bound to oriP in yeast. The interaction of EBNA1 with Rch1 was confirmed biochemically by coimmunoprecipitation
from nuclear extracts and by direct binding of recombinant proteins in vitro. Internal deletion mutations in EBNA1 which
compromised DNA replication activity were similarly reduced for binding to Rch1. Mutations with no effect on DNA replication
activity were similarly unaffected for Rch1 binding. Rch1/importin a has been shown to bind to the nuclear localization
sequence (NLS) of several proteins and stimulate nuclear import. A substitution mutation in the EBNA1 nuclear localization
sequence reduced Rch1 binding, but had no effect on DNA replication function, indicating that Rch1 binding affinity does not
correspond precisely with replication activity. Nevertheless, the identification of a stable interaction between Rch1 and
EBNA1 at the origin of viral DNA replication raises the intriguing possibility that Rch1 contributes to the nuclear functions
of EBNA1. © 1997 Academic Press
INTRODUCTION
Epstein–Barr virus (EBV) is a human gammaherpesvi-
rus which establishes a latent infection in more than 90%
of the adult population worldwide (Kieff, 1996). Latent
infection may contribute to the initiation and progression
of several human neoplasias, including Burkitt’s lym-
phoma and nasopharyngeal carcinoma. During latency,
the viral genome replicates as an extrachromosomal
circular episome that divides synchronously with the
cellular genome (Adams, 1987; Yates and Guan, 1991). A
single viral protein, EBNA1, is required for the replication
and stable maintenance of the viral genome. EBNA1
binds directly to the EBV origin of plasmid replication
(oriP) and stimulates oriP dependent replication in pri-
mate cells (Lupton and Levine, 1985; Rawlins et al., 1985;
Yates et al., 1985). EBV latent cycle replication is re-
stricted to a single round of replication per cellular divi-
sion cycle and occurs at a discrete stage in the cell cycle
S phase (Hampar et al., 1974; Adams, 1987; Sugden and
Warren, 1988; Yates and Guan, 1991). EBNA1 possesses
DNA (Rawlins et al., 1985) and RNA binding (Snudden et
al., 1994) activity, but does not demonstrate any intrinsic
enzymatic activity associated with DNA replication (Frap-
pier and O’Donnell, 1991; Middleton and Sugden, 1992).
In addition to stimulating replication, EBNA1 can also
stimulate transcription of EBV latent cycle promoters
(Reisman and Sugden, 1986; Sugden and Warren, 1989;
Gahn and Sugden, 1995). The mechanism of EBNA1
stimulation of both DNA replication and RNA transcrip-
tion is not understood, but is likely to involve the recruit-
ment of cellular factors which mediate these multiple
functions.
EBNA1 is a 641-amino-acid DNA binding protein that
binds to multiple sites within the family of repeats (FR)
and dyad symmetry (DS) element that comprise the
1.8-kb boundary of oriP (Fig. 1) (Rawlins et al., 1985;
Hsieh et al., 1993; Harrison et al., 1994). The DNA binding
and dimerization domain of EBNA1 have been mapped
to the carboxy terminal 459–607 amino acid residues
(Ambinder et al., 1991; Chen et al., 1993) and crystal
structure reveals a DNA binding structure similar to that
of the papilloma virus E2 protein (Bochkarev et al., 1995).
The amino terminal domain (aa 1–391) of EBNA1 was
found to be essential for replication function, and no
small deletion could abolish replication activity, suggest-
ing that the activation domains for replication may con-
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sist of multiple redundant modules (Yates and Camiolo,
1988; Kirchmaier and Sugden, 1997). EBNA1 binding to
oriP forms higher order DNA structures that result from
oligomerization and DNA looping (Frappier and
O’Donnell, 1992; Middleton and Sugden, 1992; Hsieh et
al., 1993; Snudden et al., 1995). The DNA linking/looping
activity associated with EBNA1 was mapped to three
independent domains rich in basic amino acid residues
(aa 54–89, 331–361, and 372–391) (Goldsmith et al., 1993;
Frappier et al., 1994; Mackey et al., 1995). A region within
FIG. 1. (A) Schematic illustration of reporter gene and expression plasmids used to generate yeast strains for the identification of EBNA1 interacting
proteins. EBV oriP sequence (;1.8 kb) was inserted into the 59 promoter region of the LacZ gene. The family of repeats (FR) and dyad symmetry
element (DS) are tandem and inverted repeats of EBNA1 binding sites. The EBNA1 gene (lacking the Gly–Ala repeats between aa 102 and 325 aa)
and an amino terminal deletion mutant, DEBNA1, (lacking aa 2–424), were expressed under the control of the GAL1/10 inducible promoter in yeast
cells. A human B-lymphocyte derived cDNA library (Clonetech) was fused to the activation domain of GAL4 and expressed under the constitutive
ADH1 promoter in yeast. (B) Summary of screening strategy shows the construction of a yeast strain with the OriP/LacZ gene integrated into the Ura3
locus, EBNA1 expressed on a TRP1 marker plasmid, and the cDNA library expressed on a Leu2 marker. ;3.5 3 106 Trp1Leu1 colonies were induced
in galactose media by replica plating in galactose media and screened for b-galactosidase activity.
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this oligomerization domain (aa 379 to 386) was capable
of conferring nuclear localization to a cytoplasmic pro-
tein (Ambinder et al., 1991). The amino terminus of
EBNA1 also contains three RGG-like motifs repeated at
amino acids 33–56, 330–350, and 354–377 which have
been hypothesized to be responsible for the RNA binding
activity (Kiledjian and Dreyfus, 1992; Snudden et al.,
1994). The amino terminal 50 amino acids share signifi-
cant sequence similarity to the amino terminus of the
human ribosomal protein S2, but the functional signifi-
cance of this remains obscure (Yates et al., 1996). Tran-
scriptional activation of both synthetic and natural EBV
promoters by EBNA1 also requires sequences in the
amino terminal domain of EBNA1 (Reisman and Sugden,
1986; Sugden and Warren, 1988; Yates and Camiolo,
1988).
To identify cellular mediators of EBNA1 function, we
designed a yeast one-hybrid assay which selects for
proteins that interact with EBNA1 when bound to oriP in
vivo. In this study, we have identified one cellular protein,
Rch1/importin a, that is capable of binding to EBNA1
when bound to oriP, as well as when free in solution,
both in vivo and in vitro. Recently, Rch1 was similarly
identified as an EBNA1 interacting protein in a two-
hybrid assay, where EBNA1 was fused to a heterologous
DNA binding domain (Fischer et al., 1997). Sequences
amino terminal to the EBNA1 DNA binding domain were
shown to be important for this interaction, but no addi-
tional correlation between binding and EBNA1 function
was presented (Fischer et al., 1997). Other studies have
revealed that Rch1 (hSRP1a, importin a, karyopherin a)
binds to nuclear localization signals (NLS) and trans-
ports proteins through the nuclear pore (Powers and
Forbes, 1994; Gorlich et al., 1995; Loeb et al., 1995; Weis
et al., 1995; Gorlich and Mattaj, 1996). Rch1/importin a
has been found to interact stably with the nuclear local-
ization signals of coilin, RAG1, LEF1, Brca1, and the influ-
enza replication protein, NP (Cortes et al., 1994; Cuomo
et al., 1994; O’Neill and Palese, 1995; Weis et al., 1995;
Chen et al., 1996; Prieve et al., 1996; Wang et al., 1996).
On the other hand, Rch1/importin a failed to interact with
several other nuclear localized proteins, including
EBNA2, RAG2, myc, max, Cdc2, and Rb, indicating that
Rch1 binds a specific subset of nuclear localized pro-
teins (Cuomo et al., 1994; Fischer et al., 1997). Importin a
has been shown to transport with nuclear target proteins
and to accumulate partially in the nucleus (Gorlich et al.,
1995; Gorlich and Mattaj, 1996). This leaves open the
possibility that importin a/Rch1 may have nuclear func-
tions in addition to that of nuclear import. In this study,
we characterize the interaction of Rch1 with EBNA1
internal deletion mutations to explore the possibility that
Rch1 binding may contribute to the DNA replication func-
tions of EBNA1.
MATERIALS AND METHODS
Plasmids
EBNA1 lacking the Gly–Ala repeat sequences between
aa 102 and aa 325 was used as a functional wild type
protein since deletion of the Gly–Ala repeat domain did not
have any effect on EBNA1’s replication activities. To simplify
the nomenclature, we refer to EBNA1 (D102–325) as
EBNA1. EBNA1 was amplified by the polymerase chain
reaction (PCR) with an amino terminal HA epitope tag
(Zhou et al., 1992). HA-EBNA1 was subcloned into pCR II
using TA vector cloning (Invitrogen) for in vitro expression
with T7 RNA polymerase. HA-DEBNA1 is an amino terminal
deletion that initiates from amino acid 425 and was
amplified with an amino terminal HA tag and subcloned in
pCR II for in vitro expression with T7 RNA polymerase.
Similarly, EBNA1(D72–338), EBNA1(D72–382), EBNA1
(D102–356), EBNA1(D102–376), EBNA1(D102–325/328–374),
EBNA1(D107–325/329–381), and EBNA1(379.GAG) were all
derived from p367 which carries oriP, the hygromycin resis-
tance gene, and the EBNA1 d17 gene (D102–325) driven by
the RSV LTR (Wysokenski and Yates, 1989; Yates and Camiolo,
1988; J.L.Y. unpublished). EBNA1 mutants were subcloned by
PCR with amino terminal HA tags into pCR II (Invitrogen) for
expression in vitro with T7. EBNA1 (379.GAG) is a substitution
mutation of the nuclear localization signal residues KRP to
GAG at positions 379–381. For establishment of stable cell
lines using retroviral insertion, HA-EBNA1 was cloned into the
unique EcoRI site of pSRaMSVtkneo (Muller et al., 1991) to
generate pLTR-HA-EBNA1. The yeast expression plasmids
pEBNA1/.04a and pDEBNA1/.04a were generated by subclon-
ing the HA-EBNA1 and HA-DEBNA1 BamHI–ClaI fragment
into the BamHI–ClaI sites of pSD.04a, a galactose inducible
yeast expression vector with a TRP11 marker (Dalton and
Triesman, 1992). The yeast expression vectors for the two
hybrid analysis were generated by cloning EBNA1 or deletion
mutants of EBNA1 (as described in the text) into the pASII
BamHI–SalI sites (Clonetech) by PCR generated restriction
sites. pRB/ASII contains the retinoblastoma gene inserted into
pASII vector. Mammalian expression vectors for HA-EBNA1
and HA-EBNA1(D102–376) were subcloned from pCR II as
EcoRI fragments into the EcoRI site of pcDL-SRa296 (Takebe
et al., 1988). Human Rch1 cDNA (hRch1) (Cuomo et al., 1994)
was isolated from pACT based human lymphocyte cDNA
library (Clonetech) initiating at amino acid 26 by sequence
comparison with the identical sequence of human SRP1a
(Weis et al., 1995). hRch1 was subcloned into pRST2 (gift of D.
Hayward) with 59 EcoRI–39 BamHI sites and used for in vitro
expression with T7 RNA polymerase. hRch1 cDNA was sub-
cloned into pGEX3T (Pharmacia) by PCR amplification with 59
BamHI and 39 EcoRI sites and used for expression of GST–
Rch1 fusion proteins in Escherichia coli. The oriP dyad sym-
metry element (HincII–EcoRV) was subcloned into pBSKII for
the generation of radiolabeled probe in DNA binding reac-
tions.
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Yeast strains
(EBV) oriP was amplified by PCR with a 59 XhoI and 39
SalI site and cloned into the XhoI site 59 to the CYC1 TATA
box in the 2-mm CYC1/LacZ reporter pLGD-178 (Guar-
ente et al., 1982). After determining that this reporter
plasmid was responsive to a VP16-EBNA1 fusion by
b-galactosidase assay, the reporter construct (oriP/LacZ)
was excised as a ScaI fragment and inserted into the
StuI site of pURA3, thus disrupting the open reading
frame of URA3. This plasmid was then used to integrate
oriP/LacZ into the URA31 locus in Saccharomyces cer-
evisiae strain S50 as described (Dalton and Triesman,
1992). Disruption was confirmed by Southern blot analy-
sis. The resulting yeast strain ura3<oriP/lacZ was then
cotransformed (Ito et al., 1983) with pEBNA1/.04a and
pcDNA/ACT1 (Clonetech), a human B-lymphocyte cDNA
library fused to the GAL4 activation domain expressed
under the control of the constitutive ADH1 promoter and
containing a LEU2 marker. For two-hybrid assays, the
yeast strain Y190 (Clonetech) was used. Liquid b-galac-
tosidase assays were performed as described (Dalton
and Triesman, 1992).
In vitro binding reactions
Proteins were in vitro translated with or without [35S]
methionine using the T7 in vitro transcription/translation
system (Promega). GST–Rch1 was expressed in E. coli
and purified by affinity chromatography on pGST-S–
Sepharose, eluted with glutathione, and dialyzed into
protein binding buffer (PBB: 20 mM Hepes (pH 7.9), 20%
glycerol, 0.5 mM EDTA, 60 mM KCl, 6 mM MgCl2, 0.1%
NP-40) (Ozer et al., 1994). GST binding assays were
performed essentially as described (Ozer et al., 1994)
except that bound reactions were washed in PBB con-
taining 150 mM KCl. Immunopurification and peptide
elution of HA-EBNA1 was performed as described pre-
viously for HA-TBP (Zhou et al., 1992). Immunopurified
proteins were subject to reimmunoprecipitation with a
second antibody raised and affinity purified against re-
combinant Rch1. For immunoprecipitation, cold and [35S]
methionine metabolically labeled nuclear extracts were
prepared essentially as described (Dignam et al., 1983),
except scaled down to accommodate 107 cells and ex-
tracted with a final buffer containing 10 mM Hepes (pH
7.9), 1 mM EDTA, 400 mM NaCl, 0.1% NP-40, 1 mM
dithiothreitol (DTT), 1 mM phenylmethylsolfonyl fluoride
(PMSF), 10 mg/ml Leupeptin, 10 mg/ml Pepstatin A. Im-
munoprecipitates were washed in this extraction buffer
three times before elution.
Establishment of stable HA-EBNA1 cell line
HeLa S3 cells were transfected with pLTR-HA-EBNA1
and pSV-w2–A–MLV and selected for colonies resistant
to 0.5 mg/ml G418 essentially as described (Zhou et al.,
1992). Positive colonies were then assayed by Western
blot for the stable expression of HA tagged EBNA1 pro-
tein by 12CA5 monoclonal antibody.
Transient DNA replication assay
Transient DNA replication assays were performed es-
sentially as described previously (Wysokenski and Yates,
1989).
RESULTS
Identification of cellular proteins that interact with
EBNA1 when bound to oriP in vivo
The 1.8-kb oriP sequence was inserted into the up-
stream control region of the LacZ gene. The oriP–LacZ
fusion was embedded in the URA31 gene of pURA3 then
integrated as a single copy into the yeast chromosome
URA3 locus. Transformation of this strain with pEBNA1/
.04a resulted in low levels of b-galactosidase expression
in galactose containing medium. When EBNA1 was
fused at the amino terminus to the activation domain of
herpes simplex VP16 (aa 410–490), high levels of b-
galactosidase were expressed, indicating that LacZ was
under the control of an activating EBNA1 protein (data
not shown). To identify human proteins that interact with
EBNA1, a human lymphocyte cDNA library fused to the
activation domain of GAL4 was transformed into the
oriP/LacZ integrated strain with EBNA1 expressed from
the galactose inducible promoter (Fig. 1). The resulting
Trp1Leu1 transformants were then assayed for expres-
sion of b-galactosidase by blue-white selection. After
screening 3.5 3 106 colonies, 45 transformants were
found to express reproducibly high levels of b-galacto-
sidase. Positive scoring cDNA were retransformed into a
yeast strain containing an EBNA1 gene fused to the DNA
binding domain of GAL4 to identify proteins that were
likely to interact with EBNA1 directly. The two-hybrid
approach as a secondary screen revealed that only four
of the original 40 isolates interacted with EBNA1 inde-
pendent of oriP (data not shown). These were sequenced
and two of these cDNA were identified as derivatives of
the human Rch1 protein. Both isolates of Rch1 were
incomplete copies, one initiating at amino acid 26 and
the other at amino acid 93. The other clones encoded
SF2 associate protein p32 (Krainer et al., 1991). Both
Rch1 and SF2 associated protein p32 were isolated
multiple times in an independent screen for EBNA1 in-
teracting proteins using the two hybrid method (J.B.H.
and J.L.Y., data not shown). We found that the interaction
of EBNA1 with Rch1 to be more reproducible and stable,
and therefore, it was characterized further.
An analysis of the interaction between EBNA1 and
Rch1 in the oriP/LacZ integrated yeast strain is summa-
rized in Table 1. High levels of b-galactosidase expres-
sion were induced only in strains that express EBNA1
343CORRELATION BETWEEN EBNA1 REPLICATION AND BINDING TO Rch1/IMPORTIN a
and Rch1. The Rch1 expression vector, pRch1/ACT,
had no effect on b-galactosidase activity in strains con-
taining the SD.04a vector. Galactose induction of EBNA1
from pEBNA1/.04a had no effect on b-galactosidase ac-
tivity in yeast strains containing the pACT vector alone.
However, galactose induction of EBNA1 in yeast strains
containing pRch1/ACT resulted in a 73-fold increase in
b-galactosidase activity. Rch1 did not interact with the
DNA binding/dimerization domain of EBNA1 (pDEBNA1/
.04a). DEBNA1 expression in yeast was confirmed by
Western blotting analysis (data not shown). These results
suggest that Rch1 binds to EBNA1 when bound to oriP in
vivo and indicate that the amino terminal domain (aa
1–424) is important for this interaction.
Rch1 interacts with EBNA1 in vitro
To determine whether the interaction between EBNA1
and Rch1 could occur in vitro, the two proteins were
translated in reticulocyte lysates and assayed for com-
plex formation by immunoprecipitation. EBNA1 and ami-
no-terminal deletion mutant EBNA1(D2–424) were fused
at the amino terminus to the HA epitope to facilitate
immunoprecipitation with the 12CA5 monoclonal anti-
body. The translational efficiency of these constructs was
shown by translation in the presence of [35S]methionine
(Fig. 2A, lanes 1 and 2). To test for an interaction between
EBNA1 and Rch1 in vitro, 35S-labeled Rch1 was incu-
bated with unlabeled in vitro translated HA-EBNA1 and
precipitated with 12CA5 monoclonal antibody. This re-
sulted in approximately 10% of the input 35S-labeled Rch1
TABLE 1
Summary of Liquid b-Galactosidase Assays in the Strain Contain-
ing the Integrated oriP/LacZ Reporter Gene with the Vector Control
pSD.04a, pEBNA1/.04a, or pDEBNA1/.04a
Plasmids Glu Gal Gal/Glu
pSD.04a 1 pACT 0.54a 1.0 2.0
pSD.04a 1 pRCH1/ACT 0.6 1.1 1.8
pEBNA/.04a 1 pACT 0.26 0.22 0.8
pEBNA/.04a 1 pRCH1/ACT 0.18 13.2 73.3
pDEBNAb/.04a 1 pACT 0.33 0.6 1.8
pDEBNA/.04a 1 pRCH1/ACT 0.58 1.24 2.1
pASII 1 CII/ACT 0.1 0.18 1.8
pRB 1 pACT 0.1 0.14 1.4
Note. The strains were compared with pACT or with pRch1/ACT.
a Numbers represent an average value of three independent exper-
iments.
b pDEBNA represents the deletion of amino acids 2–425.
FIG. 2. (A) EBNA1 binds to Rch1 in vitro. 35S-labeled in vitro translated hRch1 (lanes 3–5), luciferase (lanes 6–8), or independent isolate AL19 (lanes
9–11) was incubated with unlabeled in vitro translated HA tagged EBNA1 (lanes 4, 7, and 10) or with HA tagged EBNA1 D2–424 (lanes 5, 8, and 11)
and precipitated with the 12CA5 monoclonal antibody. 35S-labeled EBNA1 and EBNA1 D2–424 are shown in lanes 1 and 2, respectively. Lanes 3, 6,
and 9 represent 10% of the input 35S-labeled protein used for each binding reaction. Input and bound proteins were resolved on 10% SDS–PAGE gels
and labeled proteins are visualized by autoradiography. (B). Rch1 interacts with EBNA1 bound to oriP in vitro. Radiolabeled oriP DS element was
incubated with GST-Rch1 (lane 2), GST–Rch1 and EBNA1 (lane 3), GST and EBNA1 (lane 4), or GST (lane 5) and then precipitated with
glutathione–Sepharose. Bound DNA was eluted with SDS, subject to polyacrylamide gel electrophoresis and visualized by autoradiography. Bound
DNA was quantitated by PhosphorImager (Molecular Dynamics).
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coprecipitating with EBNA1 (Fig. 2A, lane 4). In contrast,
no detectable amount of Rch1 was precipitated with the
deletion mutant of EBNA1 (D2–424) (Fig. 2A, lane 5).
EBNA1 did not coimmunoprecipitate with control 35S-
labeled luciferase protein, or with a different cDNA iso-
late (AL19) that scored positive in the integrated oriP
yeast strain (Fig. 2A, lanes 7 and 10). These results
suggest that Rch1 is capable of binding to full-length
EBNA1 in vitro and that amino acids 1–424 are important
for this interaction.
Rch1 interacts with EBNA1 when bound to oriP
The yeast selection assay indicated that Rch1 could
recognize EBNA1 when bound to oriP in vivo. To confirm
this, we tested the ability of purified GST–Rch1 protein to
interact with affinity purified HA-tagged EBNA1 protein
when bound to oriP DNA in vitro (Fig. 2B). Radiolabeled
oriP dyad symmetry element was incubated with GST–
Rch1 protein in the presence or absence of affinity puri-
fied EBNA1 protein and assayed for binding to glutathio-
ne–Sepharose. After precipitation and washing, a
significant percentage of oriP DNA was retained by glu-
tathione sepharose only in the presence of GST–Rch1
and EBNA1 proteins (Fig. 2B, lane 3). In the absence of
EBNA1 or GST–Rch1, only background levels of oriP was
retained by the glutathione–Sepharose (Fig. 2B, lanes 1,
4, and 5). This result indicates that Rch1 can bind stably
to EBNA1 when EBNA1 remains bound to oriP DNA.
Rch1 binds to EBNA1 in mammalian cells
To determine if Rch1 binds to EBNA1 in human tissue
culture cells, we established a stable cell line expressing
an epitope tagged EBNA1 protein (HA-EBNA1). Western
blotting of this cell line revealed stable expression of
HA-EBNA1 migrating at an apparent molecular mass of
54 kDa (data not shown). The HA-EBNA1 cell line and a
control HeLa cell line were labeled with [35S]methionine
for 4 h. Nuclear extracts were subject to immunoaffinity
purification with the 12CA5 antibody covalently coupled
to protein A–Sepharose beads. After extensive washing
with PBB containing 400 mM KCl, proteins were eluted
with HA epitope peptide. The immunoaffinity purified
complexes were reprecipitated with an affinity purified
rabbit antibody raised against Rch1. A series of proteins
ranging from 57 to 48 kDa were recovered (Fig. 3A, lane
2) from the HA-EBNA1 expressing cells, but not from
immunopurified complexes derived from the HeLa cell
controls (lane 1). Rch1 is likely to be the 57-kDa protein
that is associated with EBNA1 affinity purified complex,
and the lower molecular mass proteins may be nonspe-
cific proteins trapped in the precipitation or degradation
products of Rch1 generated in the second round of
precipitation. To further confirm that Rch1 is present in
the immunoaffinity purified complex derived from the
HA-EBNA1 cell line, the HA-EBNA1 associated proteins
were assayed by Western blot for the presence of Rch1.
Antibody raised against Rch1 recognized only a single
band of the recombinant protein (Fig. 3B, lane 1); how-
ever, several additional bands were recognized in a
crude HeLa cell extract (lane 2). The Rch1-specific serum
recognized a distinct 58-kDa band in the anti-HA immu-
noprecipitate from HA-EBNA1 cells (lane 4), but not in
control immunoprecipitates made with an irrelevant an-
tibody (aVCA) (lane 3). Taken together, these results
suggest that Rch1 can associate with EBNA1 when ex-
pressed at near physiological levels in a stable human
cell line.
EBNA1 sequences required for Rch1 binding
Several deletion mutations of EBNA1 were tested for
their ability to interact with Rch1 in the two-hybrid assay
in yeast (Fig. 4A, Table 2). EBNA1 derivatives were fused
to the DNA binding domain of GAL4 in the pASII vector
(Clontech) and Rch1 was fused to the GAL4 transcrip-
tional activation domain in the pACT vector (Fig. 4A).
Strains cotransformed with pEB/ASII and pRch1/ACT
produced ;100-fold stimulation of b-galactosidase ac-
FIG. 3. EBNA1 binds Rch1 in mammalian cell extracts. (A) A stable
cell line expressing HA-EBNA1 was tested for its ability to interact with
endogenous Rch1. HeLa (lane 1) or HA-EBNA1 expressing cells (lane 2)
were metabolically labeled with [35S] methionine and derived nuclear
extracts were subject to immunoaffinity purification over a 12CA5 col-
umn followed by peptide elution. Eluants were then subject to a second
round of immunoprecipitation with affinity purified rabbit antibody spe-
cific for the Rch1 protein. A predominant band migrating at 58 kDa and
specific to the HA-EBNA1 derived immunoprecipitates is indicated by
the arrow. (B) Western blotting analysis of immunoaffinity purified pro-
teins from HA-EBNA1 expressing cells. Affinity purified rabbit antisera
against Rch1 was used to identify recombinant Rch1 (rRch1; lane 1) or
human Rch1 in a total HeLa cell nuclear extract (lane 2). HA-EBNA1
cells were immunoaffinity purified with 12CA5 antibody (lane 4) or with
a control monoclonal antibody, aVCA (lane 3) and then subject to
Western blotting analysis with Rch1-specific antisera (lanes 3 and 4).
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tivity relative to strains with pEB/ASII and the pACT
vector. The specificity of this interaction was demon-
strated by using the retinoblastoma protein (RB) as the
bait. pRB/ASII in combination with pRch1/ACT produced
b-galactosidase activity indistinguishable from the vec-
tor controls. The domains of EBNA1 required for the
interaction with Rch1 were partially mapped using this
two-hybrid assay. We found that deletion of the EBNA1
dimerization and DNA binding domain (aa 477–641) re-
sulted in a slight increase in b-galactosidase activity,
indicating that the amino terminal 471 amino acid resi-
dues of EBNA1 were sufficient for interacting with Rch1.
Two other deletion mutants, D2–327 and D385–641 were
reduced approximately 10-fold in b-galactosidase activ-
ity, suggesting a weaker interaction with Rch1 relative to
full-length EBNA1. Smaller domains of EBNA1 were also
tested in this assay, including the regions spanning aa
1–90 and aa 327–424 (data not shown). While these
derivatives had no activity in these assays, Western blot-
ting analysis was unable to confirm their expression.
Nevertheless, these experiments suggest that se-
quences in both the amino terminal (1–90) and central
(327–477) domain of EBNA1 contribute to the stable
interaction with Rch1.
Rch1 binding and EBNA1 DNA replication function
Six internal deletion mutations of EBNA1 which have
been previously characterized for DNA replication activ-
ity (J.L.Y., unpublished) were compared for their ability to
bind Rch1. These sets of mutations were of particular
interest since they partially distinguish two important
functional domains of EBNA1, the nuclear localization
signal (aa 379–386) and the three independent DNA
linking domains (aa 54–89, aa 331–361, aa 372–391). The
EBNA1 internal deletion mutations were first tested for
their ability to bind Rch1 in the yeast two-hybrid assay
(Fig. 4A). EBNA1 deletion mutations D72–338, D102–356,
and D102–325/328–374 all resulted in levels of b-galac-
tosidase activity similar to that of wild type EBNA1. These
mutants were also found to have at least 60% of the wild
type level of activity in transient DNA replication assays
(Fig. 5). Internal deletion mutations of EBNA1 which were
defective in replication function were also compromised
for Rch1 binding. EBNA1 mutant D72–382 had no detect-
able Rch1 binding activity and similarly no detectable
replication activity. D102–376 interacted with Rch1 with
;23% of wild type activity and is reduced to ;10–25%
replication activity. D107–325/329–381 also stimulates
replication at ;10–25% of wild type EBNA1, but showed
no detectable interaction with Rch1 in the two hybrid
assay.
To further examine the possible correlation of EBNA1
replication activity with Rch1 binding, we assayed the
ability of EBNA1 internal deletion mutants to bind GST–
Rch1 in vitro. EBNA1 internal deletion mutants were
FIG. 4. Mapping of the Rch1 binding domain in EBNA1. (A) Quan-
titation of b-galactosidase activity in the two-hybrid assay. EBNA1
deletion mutations were fused to the GAL4 DNA binding domain in
the pASII vector. Rch1 was fused to the GAL4 activation domain in
the pACT vector. pRB is the retinoblastoma protein. EBNA1 deletion
mutations are described in the text and in Table 2. Samples were
determined in triplicate with less than 20% error and the average
value is presented. (B) Interaction of GST–Rch1 with 35S-labeled
EBNA1 translated proteins in vitro. EBNA1 deletion mutations are
indicated on the left, and quantitation of bound EBNA1 proteins is
indicated to the right of each autoradiogram.
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TABLE 2
Amino Acid Sequence of the Junctions Spanning EBNA1 Internal Deletion Mutations
EBNA1 wt (D102–325) 1-95-
p367 GGAGAG.GGGRGRGGSGGRGRGGSGGRGRGGSGGRRGRGRERARGG
SRERARGRGRGRGEKRPRSPSSQSS
EBNA1 (D102–356) 1-95-
p743 GGAGAG.GRERARGGSRERARGRGRGRGEKRPRSPSSQSS
EBNA1 (D102–376) 1-95-
p744 GGAGAG.GEKRPRSPSSQSS
EBNA1 (D107–325/329–381) 1-100-
p780 GGAGAG.GGG.RSPSSQSS
EBNA1 (D72–338) 1-65
p373 HRDGVR.RGGSGGRGRGGSGGRRGRGRERARGGSRERARGRGRGR
GEKRPRSPSSQSS
EBNA1 (D72–382) 1-65-
p374 HRDGVR.SPSSQSS
EBNA1 (D102–325/328–374) 1-95-
p630.13 GGAGAG.GG.GRGEKRPRSPSSQSS
EBNA1 (379.GAG) 1-95-
p777 GGAGAG.GGGRGRGGSGGRGRGGSGGRGRGGSGGRRGRGRERAR
GGSRERARGRGRGRGEKGAGSPSSQSS
FIG. 5. Summary of Rch1 binding affinity and DNA replication activity of EBNA1 deletion and substitution mutations. Nuclear localization signal aa
379–386 (Ambinder et al., 1991), the DNA looping/linking regions aa 54–89, 331–361, and 372–391 (Goldsmith et al., 1993), and the RGG motifs
(Snudden et al., 1994) are indicated. 1Yeast two-hybrid and in vitro GST fusion protein binding analysis shown as percentage wild-type activity; 2activity
shown as percentage wild type (J.L.Y., manuscript in preparation); 3not determined in GST binding assay; 4these mutants were not tested for replication
activity since two very similar mutants were found to have less than 4% of wild-type activity (Kirchmaier and Sugden, 1997); 5these mutants were not
tested for replication activity but are expected to be inactive since they lack the DNA binding domain.
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subcloned into pCR II and radiolabeled by in vitro trans-
lation. 35S-labeled EBNA1 derivatives were compared for
their ability to bind GST–Rch1 (Fig. 4B). Mutants D102–
325/328–374, D102–356, and D72–338, which stimulate
DNA replication at least 60% as efficiently as wild type
EBNA1, bound to GST–Rch1 as well as or better than wild
type EBNA1. The EBNA1 deletion mutation D72–382,
which was inactive in DNA replication, did not show
significant binding to GST–Rch1 (Fig. 4B). D107–325/
329–381 and D102–376, which were severly reduced for
DNA replication, were similarly compromised for Rch1
binding (25 and 14% of wild type, respectively, Fig. 4B).
None of these EBNA1 deletion mutants bound to GST
control protein.
Rch1 interacts with the EBNA1 nuclear localization
signal
Several studies have shown that Rch1 and related
family members mediate nuclear translocation by direct
binding to a nuclear localization signal (Gorlich et al.,
1995; Weis et al., 1995; Chen et al., 1996; Pante and Aebi,
1996; Prieve et al., 1996; Wang et al., 1996). The EBNA1
amino acid residues 379–386 have been shown to confer
nuclear localization when transferred to cytoplasmic pro-
teins (Ambinder et al., 1991). The EBNA1 nuclear local-
ization signal was mutated by substitution of the amino
acid residues 379–381 from KRP to GAG. This mutant
EBNA1 (379.GAG) was tested for its ability to interact
with Rch1 in vivo by the two-hybrid method in yeast (Fig.
4A) and in vitro by GST–fusion interaction (Fig. 4B). In
both cases, EBNA1 (379.GAG) was reduced relative to
wild type EBNA1 for binding to Rch1. However, in both
cases, we were able to demonstrate that EBNA1 still
retained an interaction above background. By two-hybrid
analysis, we found that EBNA1 (379.GAG) was reduced
to 14% of wild type in its ability to bind Rch1 (Fig. 4A).
However, EBNA1 (379.GAG) produced b-galactosidase
activity that was 12-fold over background signals gener-
ated by the deletion mutation EBNA1 (D107–325/329–
381) or for vector alone. EBNA1 (379.GAG) bound to
GST–Rch1 in vitro with 71% of the wild-type activity. This
weak binding of Rch1 to EBNA1 (379.GAG) correlated
with the ability to stimulate oriP dependent DNA replica-
tion in vivo. EBNA1 (379.GAG) stimulates oriP dependent
replication as efficiently as wild type. Immunofluores-
cence studies also revealed that EBNA1 (379.GAG) is
partially redistributed in the cytoplasmic compartment (J.
Yates, manuscript in preparation). However, this partial
cytoplasmic localization does not reduce replication ac-
tivity, indicating sufficient concentrations of EBNA1 still
accumulate in the nucleus.
DISCUSSION
A human cDNA library was screened for proteins that
interact with EBNA1 when bound to oriP in yeast cells.
Proteins selected in this manner were considered more
likely to contribute to EBNA1 replication functions. Rch1
was selected for further characterization because of its
reproducibly strong reactivity in this assay and because
its was isolated multiple times in an independent two-
hybrid screen with EBNA1 (J.D.H. and J.L.Y., unpublished;
Fischer et al., 1997). The cellular Rch1 protein was
shown to bind to EBNA1 in vitro and in mammalian cell
nuclear extracts by immunoprecipitation (Figs. 2 and 3).
Deletion mutations of EBNA1 that disrupted DNA repli-
cation severely were found to also effect the binding to
Rch1. The interaction of Rch1 with EBNA1 is likely to
involve sequences in addition to the previously charac-
terized nuclear localization signal between amino acids
379–386. These results are consistent with the possibility
that Rch1 binding to EBNA1 may be important for func-
tions associated with stable maintenance and replica-
tion of oriP in addition to nuclear localization of EBNA1.
Rch1 was originally isolated in a two-hybrid screen for
proteins that interact with the recombinase activating
gene-1 (RAG-1) protein (Cuomo et al., 1994). Rch1 is
identical to hSRP1a, a member of the importin family of
proteins that play and essential role in reconstituted
nuclear translocation assays (Powers and Forbes, 1994;
Gorlich et al., 1995; Loeb et al., 1995; Weis et al., 1995).
hSRP1a was isolated biochemically as a component of a
complex that binds nuclear localization signals and stim-
ulates nuclear transport in vitro (Weis et al., 1995). A
yeast homolog, SRP1, was originally isolated as a sup-
pressor of a temperature sensitive RNA polymerase I
allele (Yano et al., 1992). Yeast SRP1 is an essential gene,
but its temperature sensitive mutant alleles exhibit pleio-
tropic phenotypes, including cell cycle arrest and abnor-
mal nucleolar morphology (Yano et al., 1994). SRP1 has
been genetically linked to the nuclear pore complex, and
immunofluorescence staining suggests that it localizes
to both the nucleus and cytoplasm (Belanger et al., 1994).
Yeast SRP1 was also shown to be required for the onset
of mitosis, suggesting that SRP1 may be involved in the
nuclear import of proteins critical for cell cycle progres-
sion (Loeb et al., 1995). The amino acid sequence of the
SRP1 gene revealed sequence similarity to the armadillo
and plakoglobin proteins, thus comprising a gene super-
family characterized by proteins composed of degener-
ate tandem repeats of a ;42-amino-acid domain (Yano
et al., 1994).
A Drosophila gene highly related to Rch1, pendulin/
oho, was isolated by a genetic screen for abnormal
embryonic development, suggesting that mutations in
Rch1 family members have pleiotropic effects on growth
regulation in higher eukaryotes as well (Kussel and Fra-
sch, 1995; Torok et al., 1995). Pendulin was required for
normal cell proliferation and had a dynamic cell-cycle
dependent nuclear localization (Kussel and Frasch,
1995). Pendulin was shown to accumulate in the nucleus
just prior to the onset of mitosis, suggesting a possible
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role in cell cycle regulation (Kussel and Frasch, 1995).
Overgrown hematopoietic organs (OHO) were isolated in
an independent screen for Drosophila tumor suppres-
sors (Torok et al., 1995). A mutant allele of OHO resulted
in the proliferation of hematopoietic cells and produced
melanotic tumors. Thus, Rch1 and related family mem-
bers affect nuclear functions by either the indirect regu-
lation of nuclear transport or by the direct association
with nuclear factors.
A nuclear localization signal in EBNA1 has been
mapped previously to amino acid residues 379–386
(Ambinder et al., 1991). These sequences were found to
be important for high affinity interaction between EBNA1
and Rch1 (Fig. 4). However, our data also suggest that
sequences outside of the EBNA1 nuclear localization
signal contribute to Rch1 binding. An internal deletion
mutation of EBNA1 (D102–376) which retains the nuclear
localization signal (aa 379–386) was significantly re-
duced for binding to Rch1 in vitro and in the yeast
two–hybrid assay (Fig. 4). This mutation was reduced for
DNA replication activity, but translocated to the nucleus
indistinguishably from wild type EBNA1 (data not shown).
Additionally, a substitution mutation in the nuclear local-
ization signal of EBNA1 (379.GAG) reduced the binding
of EBNA1 to Rch1, but did not completely abolish the
interaction in yeast or under moderate stringency condi-
tions in vitro (Fig. 4). This substitution mutant of EBNA1
(379.GAG) had no detectable effect on DNA replication
function. Thus, sufficient quantities of EBNA1 required
for DNA replication function can be retained in the nu-
cleus when this nuclear localization signal is interrupted.
Furthermore, this substitution mutant of EBNA1 indicates
that the nuclear localization signal at residues 379–381 is
not essential for DNA replication function. While a high
affinity interaction between the EBNA1 NLS and Rch1 is
not required for DNA replication function, a low affinity
interaction between Rch1 and EBNA1 mediated by se-
quences 356–376 may be important for EBNA1 DNA
replication activity.
We have used two distinct methods to determine the
relative binding activity of EBNA1 deletion mutants for
Rch1. These methods produced slightly different patterns
in the relative affinity between specific mutants and Rch1
(compare Figs. 4A and 4B). Several factors may account
for these differences. First, levels of EBNA1 expression
in yeast could not be controlled precisely, although de-
tectable expression of all mutants could be confirmed by
Western blotting. Second, we did observe that some
EBNA1 deletions had moderate toxicity effects in yeast,
and this may also affect levels of b-galactosidase activ-
ity. Third, we found that the in vitro binding of Rch1 to
EBNA1 was very sensitive to changes in ionic strength
and that at 400 mM KCl EBNA1 (379.GAG) was incapable
of binding Rch1, while EBNA1 (D102–325/328–374)
clearly retained binding activity (data not shown). Under
these conditions, wt EBNA1 was significantly reduced for
Rch1 binding, but detectable. Thus, some mutants of
EBNA1 may be more sensitive to in vitro binding condi-
tions than were others, and this may contribute to ob-
served differences between the two-hybrid assay and
the in vitro binding. Despite these differences in relative
affinities for EBNA1 mutants, the two interaction assays
were both consistent with our general conclusions.
EBNA1 mutants defective for DNA replication were sim-
ilarly compromised for Rch1 binding. EBNA1 mutants
completely defective for binding Rch1 were completely
defective for DNA replication. High affinity interactions
with Rch1 did not correlate with the ability of EBNA1
mutants to stimulate transient DNA replication, but
weaker affinity interactions mediated by residues amino
terminal to the NLS may correlate with EBNA1 replication
activity.
Several lines of evidence are consistent with a model
in which Rch1 binding contributes to EBNA1 nuclear
functions. First, our mutational analysis of EBNA1 shows
a reasonable, although imperfect, correlation between
the ability to bind Rch1 and the ability to stimulate DNA
replication. Second, Rch1 recognized EBNA1 when
bound to oriP in vitro and in yeast, thus being capable of
interacting with the physiologically relevant form of
EBNA1. Rch1/importin a has been shown to translocate
with the nuclear substrate to the nucleus; thus Rch1 and
EBNA1 colocalize to the nuclear compartment (Gorlich et
al., 1995; Weis et al., 1995). Rch1 has been reported to
interact stably with RAG1, coilin, Brca1, LEF1 and the
influenza virus replication protein, NP (Cortes et al., 1994;
Cuomo et al., 1994; O’Neill and Palese, 1995; Weis et al.,
1995; Chen et al., 1996; Prieve et al., 1996; Wang et al.,
1996). While the functions of these proteins are not com-
pletely understood, RAG1, EBNA1, LEF1, and NP are likely
to be bound to unusual conformations of DNA. LEF1 has
also been shown to interact with b-catenin which, like
Rch1, is a member of the armadillo gene superfamily
(Behrens et al., 1996). The interaction of b-catenin with
LEF1 in the nucleus converts LEF1 into a more potent
transcriptional activator. This raises the possibility that
Rch1 may also associate with and modify the activity of
a subset of nuclear proteins important for chromosomal
functions.
The stable interaction of EBNA1 with Rch1 may also
be considered in the context of the oncogenic potential
of EBNA1. EBNA1 is the only viral protein consistently
expressed in EBV associated Burkitt’s lymphomas (Kieff,
1996; Magrath, 1990; Rickinson and Kieff, 1996). EBNA1
can also induce tumor formation in transgenic mice, but
the mechanism by which this occurs is completely un-
known (Wilson et al., 1996; Wilson and Levine, 1992).
Mutations in yeast SRP1 and Drosophila pendulin/oho
demonstrate significant defects in cell growth and divi-
sion, suggesting that Rch1 could be a target of EBNA1
growth transforming activity (Yano et al., 1994; Kussel
and Frasch, 1995; Loeb et al., 1995; Torok et al., 1995).
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Although it is unclear if EBNA1 alters normal Rch1 func-
tion, it is conceivable that stable binding to Rch1 by
EBNA1 may interfere with growth control, as do muta-
tions in yeast and Drosophila Rch1 homolog. Thus, Rch1
may serve as a candidate target for future investigations
into the mechanism of EBNA1 mediated growth trans-
forming activity.
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